MIMOSA Diagnostics, a medical equipment manufacturing company who is making a medical device for non-invasively assessing tissue damage, has received Health Canada approval six months after it launched its technology in the U.S. The sign-off paves the way for the company to sell its MIMOSA Pro device north of the border, following comments last year by CEO Dr. Karen Cross that pursuing American approval first would ease the Canadian compliance process because the two systems have similar requirements.
MIMOSA is an OBIO® member, an alumnus of our BDSP™, H2BB™ and HealthMINT™ programs and presented at the OBIO® Investment Summit.